A newly PBS-listed oral therapy will likely become first-line for adults with eosinophilic oesophagitis who require a topical steroid, a leading gastroenterologist says.

Previously, such patients had to contend with off-label use of inhaled corticosteroids intended for asthma control, which was not ideal for delivery to the oesophagus.